文献速递浆细胞疾病

不适合移植的多发性骨髓瘤患者早期≥3级感染风险预测模型:FIRST试验分析

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.
PubMed 文献 · Leukemia · 2018-04-26

FIRST试验事后分析旨在描述治疗中出现(TE)的感染特征并研究TE≥3级感染的危险因素。1613例接受治疗患者中,340例(21.1%)在18个月内发生TE≥3级感染,其中56.2%首次≥3级感染发生于前4个月。基于1378例患者的多因素logistic回归建立预测模型,保留ECOG体能状态及血清β2微球蛋白、乳酸脱氢酶和血红蛋白水平定义高、低危组,感染率分别为24.0%与7.0%(P<0.0001),模型经三项临床试验数据验证。

要点

  • TE≥3级感染在前4个月发生率最高,定义为早期感染,且风险与治疗方案无关。
  • 预测模型纳入ECOG体能状态、β2微球蛋白、乳酸脱氢酶和血红蛋白,区分高、低危组感染率24.0% vs 7.0%(P<0.0001)。
  • 该模型可用于临床指导感染监测与预防策略。

核心结论

  • 该早期TE≥3级感染预测模型可应用于临床,以指导感染监测和感染预防策略。

研究设计与样本

  • III期FIRST试验的事后分析,纳入1613例接受治疗的不适合移植的多发性骨髓瘤患者。

主要发现

  • TE感染每月数量在治疗前4个月最高,定义为早期感染。
  • 1613例接受治疗患者中,340例(21.1%)在前18个月内发生TE≥3级感染,其中56.2%首次≥3级感染发生于前4个月。
  • 早期感染风险在各治疗组间相似。
  • 基于1378例患者的多因素logistic回归分析建立首次TE≥3级感染(前4个月)预测模型,保留ECOG体能状态及血清β2微球蛋白、乳酸脱氢酶和血红蛋白水平以定义高、低危组,两组感染率分别为24.0%与7.0%(P<0.0001),差异显著。
  • 该预测模型经三项临床试验数据验证。

关键数值与推荐

  • 高、低危组感染率分别为24.0% vs 7.0%(P<0.0001)。

临床怎么用

  • 作者认为该早期TE≥3级感染预测模型可应用于临床,以指导感染监测和感染预防策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β2-microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dumontet C, Hulin C, Dimopoulos MA, et al. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018. PMID: 29784907. doi:10.1038/s41375-018-0133-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。